Anticoagulant Comparison: Warfarin vs DOACs in India

This covers what the trial evidence actually shows across warfarin and the major DOACs, where each drug class fits clinically, monitoring and cost differences relevant to Indian prescribing, and hospital pharmacy stocking implications.

How does warfarin compare to DOACs on stroke prevention?

Systematic reviews and network meta-analyses of atrial fibrillation trials show DOACs as a class carry a significantly lower risk of stroke or systemic embolism than warfarin. Rates of major bleeding, intracranial haemorrhage and mortality are lower too. Within the DOAC class, dabigatran was the only agent superior to warfarin across all four outcomes in one major network meta-analysis; apixaban ranked highest on most individual outcomes.

This evidence base is specific to atrial fibrillation stroke prevention, the indication most anticoagulant comparison literature is built around, and does not automatically generalise to every anticoagulation indication a hospital manages, such as mechanical heart valves, where warfarin remains the standard of care.

Which bleeding risks differ between warfarin and DOACs?

Intracranial bleeding risk is substantially lower with most DOACs compared to warfarin, a consistent finding across the major trials and subsequent meta-analyses. Gastrointestinal bleeding risk, by contrast, runs higher with some DOACs than with warfarin, meaning the bleeding-risk comparison is not uniformly in the DOACs' favour once bleeding location is considered rather than treated as one combined outcome.

A patient's individual bleeding risk profile, including any history of gastrointestinal bleeding or a condition predisposing to it, is a genuine clinical variable in choosing between warfarin and a specific DOAC rather than defaulting to whichever class shows the better headline safety number.

Why does warfarin still require monitoring that DOACs don't?

Warfarin's effect varies substantially between patients, and even within the same patient over time, driven by diet, other medications and genetic variation in metabolism. Regular INR (International Normalised Ratio) testing is required to keep the patient within a safe therapeutic range. DOACs act through a more predictable, fixed mechanism on a specific clotting factor, so they skip this routine coagulation monitoring in most patients.

This monitoring difference is a genuine practical burden for warfarin, not a minor inconvenience, since a patient below range risks a clot and a patient above range risks bleeding, both requiring a dose adjustment guided by the test result itself.

Why hasn't DOAC use fully replaced warfarin in Indian clinical practice?

Cost is the central reason, and it is the crux of any real-world anticoagulant comparison in India. Warfarin is inexpensive and included on India's National List of Essential Medicines. DOACs carry substantially higher per-tablet cost and sit outside that list, making warfarin the more accessible option for many patients despite its monitoring burden.

Reliable INR testing infrastructure, which warfarin depends on, is also unevenly available outside larger hospitals and urban labs, which cuts both ways: it is an argument for DOACs where testing access is poor, but DOAC affordability is the more common limiting factor in practice.

Does patient preference differ meaningfully between warfarin and DOACs?

Yes. Studies directly comparing patient experience report greater satisfaction with DOACs than with warfarin, largely attributable to the absence of routine blood testing and dietary restriction that warfarin's vitamin K interaction requires. This preference difference is a genuine clinical consideration in long-term adherence, since a regimen a patient finds burdensome is more likely to be taken inconsistently over years of therapy.

Patient preference alone does not override a genuine cost or access barrier, however, and a prescribing decision in the Indian setting has to weigh preference against what the patient or the health system can actually sustain paying for over years of anticoagulation.

Does hospital pharmacy stocking affect anticoagulant continuity of care?

Anticoagulation is rarely a short course. Both warfarin and DOAC prescriptions typically run for months to years, and an interrupted supply carries a real clotting or bleeding risk. When the in-house pharmacy doesn't reliably stock the anticoagulant prescribed, especially a less commonly stocked DOAC, the patient sources it from an outside chemist instead, breaking the treating doctor's ability to track adherence and interaction risk together.

A managed hospital pharmacy keeps a long-duration, safety-critical prescription like an anticoagulant inside the hospital's own dispensing record rather than leaking it to an external chemist, the same continuity and revenue loss covered in our prescription leakage guide.

Sources

1. 1Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis — PMC, National Institutes of Health
2. 2Systematic Review and Meta-Analysis of Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation With Low Stroke Risk — PubMed, National Institutes of Health
3. 3Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences — PubMed, National Institutes of Health
4. 4National list of Essential Medicines (NLEM) 2022 — Indian Council of Medical Research
5. 5Central Drugs Standard Control Organisation — Drugs and Cosmetics Act, 1940 and Rules, 1945

This article is for informational purposes for clinicians and hospital administrators and is not a substitute for professional medical advice. It contains no dosage instructions. Consult a qualified physician for any individual treatment decision.